Anne Li Feburary 11th, 2016
Results from a clinical trial suggest that a targeted drug that’s linked to a radioactive isotope to help kill tumor cells may soon be a new treatment option for some patients with advanced neuroendocrine tumors (NETs). Patients in the phase III trial had tumors that were progressing despite treatment with standard first-line therapies. Those who were treated with the new drug, 177Lu-Dotatate, lived substantially longer without their cancer progressing than patients who received high doses of octreotide LAR. The findings also suggest that the drug may improve how long patients live overall. But longer follow up is needed before it’s clear whether that’s the case, said the trial’s lead investigator, Jonathan Strosberg, M.D., of the Moffitt Cancer Center in Tampa, FL.
See original article at: https://www.cancer.gov/news-events/cancer-currents-blog/2017/new-treatment-neuroendocrine-tumors